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The retinoid acid receptors (RAR) and peroxisome proliferator-activated receptors (PPAR) have been implicated in the regulation
of inﬂammatory reactions. Both receptor families contain ligand-activated transcription factors which form heterodimers with
retinoid X receptors (RXR). We review data that imply RAR/RXR and PPAR/RXR pathways in physiological reactions after spinal
cord injury. Experiments show how RAR signaling may improve axonal regeneration and modulate reactions of glia cells. While
anti-inﬂammatory properties of PPAR are well documented in the periphery, their possible roles in the central nervous system
have only recently become evident. Due to its anti-inﬂammatory function this transcription factor family promises to be a useful
target after spinal cord or brain lesions.
Copyright © 2007 S. van Neerven and J. Mey. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
During the last decade much progress has been made dis-
entangling the physiological responses after central nervous
system (CNS) injury. Yet, there is still no eﬀective treatment
available to prevent the devastating eﬀects that result from
major CNS lesions. Although neurite sprouting and axonal
growth is observed after spinal cord injury (SCI), successful
regeneration beyond the lesion-induced scar does not occur.
In contrast, axonal regeneration with functional recovery is
possible in the peripheral nervous system (PNS). The dif-
ferent outcomes of CNS and PNS lesions are largely due to
diﬀerences in the cellular and molecular signals that neurons
encounter in these environments. Three important problems
after CNS injury are (1) development of a growth inhibitory
glial scar, (2) secondary neuronal and glial degeneration as a
delayed consequence of the lesion, and (3) the failure of ax-
onalregenerationinwhitemattertracts.Respondingtothese
problems, most attention has been directed either to over-
come the inhibitory barrier of the glial scar or to promote
the growth of axon collaterals and thus compensate for per-
manently severed connections [1–3]. A subsidiary approach
is to modify inﬂammatory reactions in order to limit the sec-
ondary degeneration. Synthetic corticosteroids, e.g., methyl-
prednisolone,aretheonlypharmacologicaltoolscurrentlyin
clinical use [4]. In this review, we will discuss two nuclear re-
ceptor families that have recently been discovered as possible
therapeutic targets for the treatment of SCI and brain dam-
age. Retinoic acid receptor (RAR) signaling may improve ax-
onal regeneration, inﬂuence glial diﬀerentiation, and mod-
ulate inﬂammatory reactions [5]. Peroxisome proliferator-
activated receptors (PPAR) have a major function in anti-
inﬂammatory processes [6]. Both receptor classes, RAR and
PPAR, heterodimerize with retinoid X receptors (RXR) to
form active transcription factors.
2. ENDOGENOUS RAR/RXR AND PPAR/RXR ACTIVITY
IN THE INJURED NERVOUS SYSTEM
2.1. RAR/RXRsignaltransduction
The RAR/RXR transcription factor complex is activated by
ligand binding, its natural ligand being all-transretinoic acid
(all-trans RA). Retinoids are obtained from the diet in the
form of vitamin A (retinol and retinal), retinyl esters, or β-
carotene. Following cellular uptake of all-trans retinol from
the plasma, the intracellular synthesis of retinoic acid oc-
curs in two steps. (1) Retinol is oxidized to retinal, predomi-
nantly involving the alcohol dehydrogenases ADH-1, -3, and
-4. (2) The critical step is the subsequent oxidation of retinal
to retinoic acid by retinaldehyde dehydrogenases (RALDH)
[7]. Retinoic acid is released in a paracrine or autocrine fash-
ion. The fact that RA activates nuclear transcription factors2 PPAR Research
was discovered in 1987 [8, 9]. Retinoid receptors belong to
the same superfamily as PPAR, thyroid hormone receptors
(TR), and steroid receptors. They can be grouped into two
families,theRARsandtheRXRs,eachconsistingofthreeiso-
formsencodedbyseparategenes:RARα,RARβ,RARγ (also:
NR1B1-3)andRXRα,RXRβ,RXRγ (NR2B1-3).All-transRA
and 9-cis RA bind to the RAR family, whereas only 9-cis
RA is a high-aﬃnity ligand for the RXR [7, 10]. The active
transcription factor complex consists of an RAR/RXR het-
erodimer, ligand, and coactivators. It interacts with retinoic
acid response elements (RARE) in the promoters of target
genes. About 500 genes have been suggested to be regulated
by RAR/RXR signaling, however a much lower number was
experimentally shown to be activated via the classical RARE
driven pathway. Proven target genes include enzymes, tran-
scriptionfactors,cytokines,andcytokinereceptors[5,11].In
addition, many cases of gene suppression and nongenomic
modes of action of RA and its receptors have been described
[7].
2.2. RAR/RXRsignalingafterspinalcordinjury
The discovery that enzyme activity of a retinaldehyde de-
hydrogenase increased after spinal cord contusion injury
was the ﬁrst direct evidence that retinoids play a role in
the physiological responses to SCI. Contusion injury caused
a signiﬁcant increase in RALDH2 enzyme activity, which
peaked 8–14 days following the lesion [12]. While in the
noninjured rat spinal cord RALDH2 is only present in the
meninges, oligodendrocytes and in pericytes, around the le-
sion site, its immunoreactivity also appeared in a popula-
tion of NG2-positive glia cells [13]( Figure 1(a)). NG2 is a
chondroitin sulfate proteoglycan, expressed in cells that have
been described as oligodendrocyte precursor cells, synan-
tocytes or polydendrocytes. These cells respond to injury
with increased production of NG2 and a subpopulation of
them, close to the lesion site, appears to be involved in the
local production of RA. Alternatively or additionally, RA-
synthesizingcellsmigratefromtheadjacentarachnoidmem-
brane and from blood vessels toward the site of injury [13].
While only minor changes in the quantitative expression of
retinoid receptors were observed after SCI, their cellular dis-
tribution changed remarkably (Figures 1(b), 1(c)). In the
noninjured tissue, retinoid receptors were found in the cy-
tosol of motorneurons and glia, but close to the injury site
macrophages and surviving neurons displayed a nuclear lo-
calization of RARα,R X R α,a n dR X R β [14]. In the context of
locally rising RA synthesis, the observation that retinoid re-
ceptorstranslocateintothecellnucleiindicatesthatneurons,
glia, and macrophages are targets of RA signaling after SCI.
This interpretation is consistent with data on spinal cord de-
velopment,whereRAhasbeenshowntobearegulatorofcell
diﬀerentiation [15–18].
2.3. RAR/RXRsignalingafterperipheralnerveinjury
RA signaling is implicated in the diﬀerentiation of neu-
rons whose axons grow in the PNS, [19–22] and again in
neurite regeneration [23, 24]. Several mediators of the RA
signaling pathway have been shown to be induced after
peripheral nerve injury in the rat. Experimental lesion of
the sciatic nerve induced expression of the cellular retinol
binding protein-I (CRBP-I) [25], which is implicated in
retinoid metabolism [26]. Similarly, transcript and protein
concentrations of the cellular retinoic acid binding protein-
II (CRABP-II) increased strongly [25]. CRABP-II is prob-
ably involved in the intracellular transport of RA to the
cell nucleus [27]. As after SCI, the RA-synthesizing enzyme
RALDH2was present in the injured nerve. After sciatic nerve
injury in transgenic reporter mice, local activation of RARE
was detectable in the regenerating nerve, indicating that
RA-dependent gene expression is induced during peripheral
nerve regeneration [25]. The expression of retinoid recep-
tors also changed signiﬁcantly. Following sciatic nerve crush,
mRNA of all RARs and of RXRα was increased, and at 4, 7,
and 14 days after the injury protein levels of RARα,R A R β,
and RXRα were augmented [28]. To study Wallerian degen-
erationintheabsenceofaxonalregeneration,thedistalnerve
segment can be cut oﬀ and sutured to the peroneus muscle.
Under these conditions RARα and RARβ were upregulated
in the degenerating nerve.
Cell culture experiments indicated that RARβ is required
for RA-induced axonal regeneration [24]. Consequently, ex-
periments with RARβ-deﬁcient mice corroborated this in-
terpretation because there were signiﬁcantly less GAP43-
positive, regenerating axons after sciatic nerve crush in the
knockout animals [29]. Since RALDH2 [23]a n dR A R β [30]
are induced by NGF, RA appears to act downstream of
this neurotrophin. RA/RARβ signaling seemed to be neces-
sary for the neurotrophic activity of NGF [23]. In addition,
neurotrophin-independent RA/RARβ activity contributes to
axon outgrowth [29]. Double labeling with cell type spe-
ciﬁc markers in the sciatic nerve demonstrated expression of
retinoid receptors mostly in macrophages and Schwann cells.
InculturedprimarySchwanncells,RAdownregulatedCNTF
[31] and raised expression of ErbB3, a neuregulin receptor
that is necessary for normal myelination. Finally, RXRα la-
beling was shown to colocalize with some regenerating ax-
ons,indicativeofadirectroleforRXRαinnerveregeneration
[28].
2.4. PPAR/RXRsignaltransduction
Peroxisome proliferator-activated receptors belong to the
same superfamily as the RAR. The ﬁrst PPAR was discov-
ered, cloned, and sequenced in 1990, and it was named af-
ter its property to be activated by drugs that cause pro-
liferation of peroxisomes in hepatocytes [32]. Until now,
three diﬀerent isoforms of PPAR, encoded by separate genes,
have been identiﬁed: PPARα (NR1C1), PPARβ/δ (NUC1,
NR1C2), and PPARγ (NR1C3). The diﬀerent isoforms have
similar structural features, however each isoform exhibits its
own speciﬁc tissue expression pattern and distinct physio-
logical functions depending on ligand activation [33, 34].
PPAR also heterodimerize with RXR, then bind as a com-
plex to their response elements (PPRE).These consist ofS. van Neerven and J. Mey 3
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Figure 1: Retinoic acid synthesis and nuclear translocation of RAR/RXR after spinal cord injury. (a) Double immunostaining of rat spinal
cord sections shows RALDH-2 immunoreactivity (red) in a subpopulation of NG2-positive glia (green) 7 days after contusion injury.
RALDH2/NG2 expressing cells were only detected in the vicinity of the lesion site, many NG2 cells do not contain the RA-synthesizing
enzyme (yellow arrow heads). White arrows point to DAPI-stained cell nuclei of RALDH2/NG2 cells in superimposed photographs. (b) At
7 dpo, ED1-positive macrophages at the lesion site express RXRβ in their cell nuclei. (c) SCI-induced transient translocation of RARβ and
RXRα from the cytosol into the nuclei of activated macrophages/microglia. All scale bars are 20μm (sources: [12, 14]).
two repeats of the consensus sequence AGGTCA separated
by one or two nucleotides (direct repeats DR-1 and DR-2)
[35]. Natural ligands of PPAR are fatty acids, prostaglandins,
and oxidized fatty acid derivatives. They are also activated
by synthetic ligands like the lipid-lowering ﬁbrates and the
anti-diabetic glitazones [36]. PPAR, which have been im-
plicated in lipid metabolism, cellular proliferation and in-
ﬂammatory responses, are widely expressed, for example, in
colon, spleen, retina, the cardiovascular system, liver, skeletal
muscles, and in adipose tissue. Their expression by mono-
cytes, dendritic cells, endothelial cells, megakaryocytes, and
lymphocytes may be related to immune functions [34, 36].
PPARγ can also inﬂuence gene expression independently of
PPRE. The activity of a number of transcription factors, for
example, NFκB, AP-1, and STAT-1, are inhibited by PPARγ
via direct interaction or by competition for limiting supplies
of coactivators [6].
2.5. PPAR/RXRsignalingafterspinalcordinjury
PPARareexpressedinthedevelopingandadultCNS.PPARα
and PPARβ/δ,b u tn o tP P A R γ were found in cervical, tho-
racic, and lumbar segments of the adult spinal cord, in the
thalamus and cerebral cortex [37]( Figure 2). Immunohis-
tochemical staining showed that PPARβ/δ is the main iso-
form present in neuronal cell bodies of the spinal cord gray
matter. Both receptors, PPARα and PPARβ/δ,w e r ec o n c e n -
trated in cell nuclei. In the white matter PPARα appeared
particularly strong in PPARβ/δ-negative astrocytes, whereas
oligodendrocytes expressed only PPARβ/δ [38]. PPARβ/δ is4 PPAR Research
af a c t o ri nn e u r o n a ld i ﬀerentiation, and functions of this re-
ceptor in various aspects of neural physiology have been sug-
gested [38, 39]. While in two studies PPARγ could not be
detected in brain and spinal cord [37, 38] ,t h i sr e c e p t o ri se x -
pressed in microglial primary cultures [40] and may be up-
regulatedafterinjury.Inadiﬀerentreport,allPPARandRXR
were found immunohistochemically throughout the adult
rat CNS [41].
Endogenous PPAR ligands may play a role in modulat-
ing the inﬂammatory response after SCI, possibly preventing
the expansion of the initial damage. Genovese and cowork-
ers [42] examined the eﬀects of endogenous PPARα ligands
in an experimental model of spinal cord trauma. SCI was in-
duced in wild-type and in PPARα-deﬁcient (−/−)m i c e .T h e
injury resulted in severe trauma characterized by edema, loss
of myelin, neutrophil inﬁltration, apoptosis, and increased
production of TNFα. Compared to wild-type animals, all
these parameters were augmented in PPARα−/− mice. The
absence of PPARα also interfered with recovery of limb func-
tion [42]. Studies using animal models of chronic pain indi-
cate that PPARα is involved in the neural processing of pain
[43, 44].
3. REGULATION OF INFLAMMATORY
PROCESSES BY RAR/RXR SIGNALING
IN THE SPINAL CORD
Although the inﬂammatory response limits the eﬀects of a
pathogenic insult, it is also responsible for most of the sec-
ondary damage incurred after spinal cord injury. The regula-
tion of these events is therefore of primary therapeutic con-
cern.Bothpathways,RAR/RXRandPPAR/RXRsignalingare
implicated.
3.1. Inﬂammatoryreactionsinthespinalcord
The physiological events following spinal cord injury can
be diﬀerentiated into an acute phase (the ﬁrst 24hrs), fol-
lowedbyasubacutephase(24–72hrs),andalatephase(3–90
days). Events after this time are considered chronic. CNS in-
jury directly leads to release of inﬂammatory signals result-
ing in the production of vasoactive mediators and chemo-
tactic factors. Primary damage consists mainly of severed
axons, neuronal and oligodendrocyte cell death. Expansion
of the initial damage is then caused by a disruption of the
blood supply and an extended inﬂammatory reaction. De-
pending on the type of injury, the blood-brain barrier is dis-
rupted. This event determines the extent to which blood-
derivedcellsparticipateintheinﬂammatoryprocess[45,46].
When the blood-brain barrier breaks down, the release of
cytokines and chemokines leads to a massive recruitment of
inﬂammatory cells from the periphery, including hematoge-
nous neutrophils and perivascular/meningeal macrophages.
These cells contribute to tissue damage by the production of
proteolytic enzymes and reactive oxygen species. Microglia
and macrophages phagocytose dead or injured neurons and
glia, and are responsible for the clearance of cellular debris
[45].
Microglia, perivascular macrophages, and activated as-
trocytes are the most important local sources of cytokines.
Astrocytes are further involved in the formation of a glial
scar, thereby insulating the healthy tissue from uncontrol-
lable processes in the damaged area. Acute inﬂammation can
develop into a chronic process when feedback mechanisms
fail to inhibit ampliﬁcation of the inﬂammatory response.
Chronic inﬂammation leads to a continuous inﬂux of neu-
trophils, macrophages, lymphocytes, and eosinophils from
thecirculation,causingmoretissuedestructionandscarring.
3.2. RAR/RXRsignalingisinvolved
ininﬂammation
Before the molecular mechanisms of the retinoid signal-
ing pathway were understood, anti-inﬂammatory proper-
ties of RA had already been described. In 1983, a study
showed that oral administration of retinoids aﬀected der-
mal inﬂammatory cells and reduced elevated skin tempera-
ture [47]. Retinoic acid has beneﬁcial eﬀects in diseases with
an inﬂammatory-based pathology including asthma, arthri-
tis, and atherosclerosis [48, 49]. A number of cell culture
studiessupportthehypothesisthatRAreducesinﬂammatory
activation of monocytes, macrophages, myeloma cells, and
polymorphonuclear cells (neutrophil granulocytes). Signals
that were found to be downregulated by retinoids include
IL-1α,I L - 1 β,I L - 6 ,T N F α, IL-8, prostaglandin E2,p r o d u c -
tion of reactive oxygen species, and release of lysosomal en-
zymes. A table with these eﬀects and references is presented
in [5]. In contrast to a majority of ﬁndings that indicate an
anti-inﬂammatory role of RAR/RXR signaling, it was also re-
portedthat9-cisRAinducedsecretionofMCP-1andthereby
stimulated monocyte migration [50]. In combination with
T-cell stimulating agents, all-trans RA, 9-cis RA, and an RAR
agonist, TTNPB, indirectly increased proliferation of human
Tl y m p h o c y t e sa n dI L - 2s e c r e t i o n[ 51].
One of the major transcription factors responsible for
the regulation of inﬂammatory cytokines is NFκB. It was
shown that RXR inhibits NFκB-dependent gene expression
(IL-12) [52]. In the experiments, interference of RXR with
DNA binding of NFκB required the presence of the RXR lig-
and 9-cis RA. The negative RXR/NFκB interaction appears
to be mutual because increasing levels of transfection with
NFκB subunits also abrogated expression of a retinoid re-
porter construct [52].
3.3. TheroleofRAR/RXRininﬂammatoryreactions
afterCNSinjury
Although retinoic acid has so far not been used to mod-
ify inﬂammatory reactions in the CNS in vivo, cell culture
experiments demonstrate anti-inﬂammatory eﬀects on mi-
croglia and astrocytes [5]. Primary cultures of microglia and
astrocytes are most frequently prepared from cerebral cor-
tex of perinatal rats and mice. One can expose these cultures
to LPS to simulate a bacterial infection, or treat them with
β-amyloid peptide (Aβ) to mimic the immunogenic stim-
ulus of Alzheimer’s disease. In this kind of experiment, RAS. van Neerven and J. Mey 5
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Figure 2: Localization of PPARα and PPARβ/δ in astrocytes and oligodendrocytes in the spinal cord. (a) Western blotting shows PPARα and
PPARβ but not PPARγ in spinal cord, telencephalon, and diencephalon. Identical expression patterns were detected with RT-PCR. (b) De-
tection of PPAR immunoreactive cells in the white matter of rat spinal cord. GFAP-positive/CNPase-negative astrocytes are immunoreactive
for PPARα (marked a, upper four panels) while GFAP-negative/CNPase-positive oligodendrocytes express PPARβ (marked ol, lower panels)
(scale bars: 25μm,s o u r c e :[ 38]). (c) Distribution of PPARβ/δ and PPARγ immunoreactive cells in the spinal cord of the adult rat (cervical
level, coronal sections, scale bar: 100μm,s o u r c e :[ 41]).
treatment suppressed the induction of TNFα and iNOS. Ef-
fects correlated with enhanced expression of RARβ,T G F β,
and inhibition of NFκB nuclear translocation [53]. Xu and
Drew demonstrated that 9-cis RA suppressed LPS-induced
production of NO as well as of proinﬂammatory cytokines
TNFα,I L - 1 β, and IL-12p40 in primary mouse microglia,
while IL-6 secretion and MCP-1 production were not signif-
icantly aﬀected (Figure 3)[ 54]. In astrocytes from rat brain
and in C6 astroglioma cells, 9-cis RA and all-trans RA inhib-
ited IFNγ-induced inﬂammatory responses [55].
Matrix metalloproteinases (MMP) are involved in the
breakdown of the extracellular matrix and other proteins.
T h e s ep r o t e a s e sa r ep r o d u c t so fl e u k o c y t e sa n de n d o t h e -
lial cells and are released in response to various cytokines
and growth factors. Increased proteolytic activity of MMP
can lead to disruption of the blood-brain barrier and es-
calate the inﬂammatory response [56, 57]. Retinoic acid
has negative eﬀects on secretion and expression of these
enzymes. It reduced mRNA, protein synthesis, and secre-
tion of MMP-9 (gelatinase B) in lymphocytes from pa-
tients with chronic B-lymphocytic leukemia and in human
monocytes[58].OthermetalloproteinasesincludingMMP-1
and MMP-13 appeared to be inﬂuenced by RA as well
[59].6 PPAR Research
4. REGULATION OF INFLAMMATORY
PROCESSES BY PPAR/RXR SIGNALING
IN THE SPINAL CORD
4.1. PPAR/RXRsignalingcounteracts
inﬂammatoryprocesses
For the PPAR family, anti-inﬂammatory eﬀects are well
documented. One mechanism involves direct interaction of
PPAR with proinﬂammatory transcription factors, most im-
portantly NFκB and AP-1, and the subsequent reduction of
gene transcription. This has been observed in vitro in hu-
man vascular endothelial cells [60], human aorta smooth
muscle cells [61], in C2C12 skeletal muscle cells (in a model
for insulin resistance in type 2 diabetes) [62], and in ﬁbrob-
lasts from rheumatoid arthritis patients [63]. PPAR knock-
out studies supplement and conﬁrm these results. One of
the ﬁrst reports indicating that PPARα is involved in at-
tenuating inﬂammation demonstrated that the eicosanoid
LTB4 binds and activates PPARα. Subsequently, PPARα-
deﬁcient mice were shown to have a prolonged inﬂamma-
toryresponsewhenchallengedwithLTB4 orarachidonicacid
[64].
An interaction of PPARα withNFκB is indicated by stud-
ies of inﬂammatory cytokine production in aging. In aged
mice, NFκB becomes constitutively active in many tissues
due to oxidative stress, which eventually leads to the produc-
tion of cytokines. Administration of PPARα activators was
found to restore the cellular redox balance, to suppress the
constitutive activation of NFκB and to eliminate the sponta-
neousproductionofIL-6andIL-12[65,66].Otherexamples
where PPARα−/− mice suﬀer from more severe inﬂamma-
toryreactionsarecarrageenan-inducedhypersensitivity[67],
airway inﬂammation [68], and experimental colitis [69].
On the molecular level, these investigations demonstrated
Fas-ligand, IL-1β,T N F α, keratinocyte-derived chemokine,
MIP-2, MCP-1, ICAM-1, and enzyme activities of MMP-9,
myeloperoxidase, and iNOS to be inﬂuenced by PPARα sig-
naling [67, 69, 70].
PPARγ-deﬁcient mice die in utero, but heterozygotic
PPARγ+/− mice with 50% expression of the receptor sur-
vive and can be studied. In an investigation of PPARγ func-
tions after intestinal and gastric ischemia/reperfusion injury,
PPARγ+/− mice displayed more severe lesions of the gastric
intestinal mucosa. Treatment with the PPARγ ligand BRL-
49653 limited the damage of intestinal injury and resulted in
downregulation of cell adhesion molecules and proinﬂam-
matory cytokines in the intestine and stomach [71, 72]. As
mentioned before, NFκB and inﬂammatory mediators are
raisedduringtheagingprocess.Whilethisisaccompaniedby
reduced PPARγ levels,thePPARγ ligand2,4-TZDwasshown
to reduce age-related oxidative stress, the translocation of
NFκB p65 subunit to the nucleus and NFκB-regulated tran-
scription of iNOS, COX-2, IL-1β, IL-6, and the cell-adhesion
molecule VCAM-1 [73]. Another PPARγ agonist, rosiglita-
zone, relieved renal injury in a nephrotoxicity model, also
acting via inhibiton of NFκB[ 74]. It seems therefore that
bothreceptorsPPARαandPPARγ playageneralroleinmod-
ulating the inﬂammatory response in a wide variety of tis-
sues.
4.2. EffectofPPARactivationonmacrophages,
microglia,andastrocytes
Given that PPAR agonists inﬂuence peripheral macrophages
[75], it was to be expected that they act on brain
macrophages after disruption of the blood-brain barrier.
PPARα is already present in undiﬀerentiated monocytes,
while PPARγ expression is induced during diﬀerentiation
[76, 77] and upregulated in the course of macrophage ac-
tivation [78–82]. A number of cell culture studies with
macrophages and microglia demonstrate that agonists of
PPARα and PPARγ elicit the same anti-inﬂammatory eﬀects
that we have discussed above. When cells were activated with
bacterial antigens or Aβ, the PPAR ligands typically pre-
ventedorreducedtheinﬂammatoryresponse.Thiseﬀectwas
observed on the following levels: (1) activity of transcription
factors NFκB, AP-1, and STAT-1, (2) secretion of proinﬂam-
matory cytokines and chemokines, (3) enzyme activities of
COX-2, iNOS, and MMP-9, and (4) the formation of reac-
tive oxigen radicals. A synopsis of these results is presented
in Table 1.
Such eﬀects were observed with natural ligands, for ex-
ample,prostaglandins,withartiﬁcialPPARactivators,forex-
ample, antidiabetic thiadiazolidinones, and with nonsteroid
anti-inﬂammatory drugs [83]. A very eﬃcient endogenous
agonist of PPARγ is the prostaglandin 15d-PGJ2 [70]. How-
ever, this drug also interferes with the transcriptional activity
of NFκB independently of PPARγ activation because overex-
pression of PPARγ or an antagonist of PPARγ did not alter
the 15d-PGJ2 eﬀect on LPS/IFNγ-dependent inﬂammatory
reaction.Itwasconcludedthat15d-PGJ2inhibitstheinﬂam-
matory response by directly regulating the NFκBa n dP I 3 K -
Akt pathways [79, 84].
With respect to microglia eﬀects on nerve cells, PPAR
activation with synthetic ligands can be neuroprotective.
When cortical neurons were exposed to the cell-free su-
pernatant from activated microglia, neurons survived better
when microglia had also been incubated with PPARγ ago-
nists [85]. Some experiments in vivo also support this con-
cept. Oral administration of pioglitazone or the nonsteroidal
anti-inﬂammatory drug ibuprofen, which is also a ligand for
PPARγ, reduced the number of activated microglia and re-
active astrocytes in the hippocampus and cerebral cortex.
This was observed in 10-month-old APPV717I mice, an in-
ﬂammation model for Alzheimer’s disease [83]. Pioglitazone
protected mice also from MPTP-induced dopaminergic neu-
ronal cell loss and mitigated inﬂammatory response by mi-
croglia in an animal model of Parkinson’s disease [86].
As mentioned before, astrocytes participate in the secre-
tion of cytokines and form a glial scar around the damaged
tissue. Since the production of microglia primary cultures
also involves isolation of astrocytes, it was a straightforward
approach to test PPAR agonists on this type of glia as well
(Figure 3)[ 87–89]. Results, which were generally in line with
the anti-inﬂammatory eﬀects on microglia, are also included
in Table 1.S. van Neerven and J. Mey 7
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Figure 3: Anti-inﬂammatory eﬀects of PPAR and RAR agonists in astrocytes. Astrocyte primary cultures from cortices of newborn mice
were treated with 9-cis RA (RA) and/or the PPARα agonist fenoﬁbrate (F) for 1hour and then stimulated with 2μg/mL LPS for 24 hours.
(a) Nitrite production as an indicator of NOS activity was reduced by 1μM RA or 100μM F, and completely suppressed with RA plus F.
Pretreatment of RA and/or F also decreased the release of (b) the chemokine MCP-1 (RA: 2μM,F :2 0 0 μM), and cytokines (c) IL-1β (RA:
1μM,F :1 0 0 μM), (d) IL-6 (RA: 2μM,F :5 0 μM), and (e) TNFα (RA: 1μM, F: 100μM) in response to LPS. Cytokine production was measured
with ELISA. Experiments with microglia cultures revealed similar eﬀects, except for MCP-1, whose production was stimulated by 9-cis RA
in microglia. Error bars indicate SEM, asterisks indicate signiﬁcant diﬀerences compared to the LPS condition (sources: [54, 78]).
5. APPLICATION OF RETINOIDS AND PPAR
LIGANDS AFTER SPINAL CORD AND
PERIPHERAL NERVE INJURY
Retinoic acid is a well-characterized morphogenetic factor in
embryonic development. Stem cells and several cell lines can
be induced with RA to diﬀerentiate to a neuronal phenotype.
A number of experiments with developing sympathetic neu-
rons and with sensory neurons from dorsal root ganglia re-
v e a l e dt h a tR Ah a sn e u r o t r o p h i ce ﬀects or induces neurite
growth. The question arises whether these properties can be
exploited to support axonal regeneration [5, 90].8 PPAR Research
5.1. Retinoicacid-inducedaxonalgrowthin
vitroandinvivo
While the most convincing demonstration that RA can act as
an axon-guiding chemoattractant was recently published us-
ingthesnailLymnaeastagnalis[91],anumberofearlierstud-
ies indicated that retinoids may fulﬁll similar functions in
vertebrates. Neurites extending from chick neural tube cells
responded to a gradient of RA [92]. Positive eﬀects on axon
outgrowth were also reported using explants from murine
embryonic spinal cord [93], embryonic cerebellum [94], and
amphibian spinal cord [95]. In a chick retinal explant assay,
RAenhancedneuriteoutgrowthundertheconditionthatthe
neurotrophin BDNF was subsequently added in vitro [96].
RA supported survival and morphological diﬀerentiation of
cultured rat spinal cord neurons and increased neurite den-
sity. In this context, astrocytes were implicated as regulators
of local RA concentration [16, 17].
Corcoran, Maden, and coworkers suggested that the loss
of regeneration in the adult mammalian CNS is related to
developmental changes in retinoid signaling. They observed
that the RARβ2 receptor, which is present when neurite out-
growth occurs from embryonic spinal cord explants, was not
detectable in the adult spinal cord [97]. A supporting result
was that speciﬁcally RARβ mediated the induction of neu-
riteoutgrowthfromsubpopulationsofsensoryneurons[24].
In addition to the inhibitory glial environment [1], intrinsic
changes in CNS neurons have been assumed to be responsi-
ble for the loss of regenerative ability during CNS develop-
ment [98]. The declining expression of RARβ2m a yb eo n e
of those changes. To test this hypothesis, the RARβ2g e n e
wastransfectedintospinalcordexplantswithalentiviralvec-
tor. This treatment allowed the outgrowth of many neurites,
implying the involvement of RARβ2i na x o n a lr e g e n e r a t i o n
[97]. Consequently, to demonstrate that a renewed expres-
sion of the appropriate receptor mechanism might induce
axonal regeneration into the spinal cord in vivo, Wong and
others [99]t r a n s f e c t e dR A R β2 in adult rats. They then ana-
lyzed regeneration of sensory axons into the spinal cord and
performed behavioral experiments. Following complete dor-
sal root transections by means of a crush injury, axons re-
generated across the dorsal root entry zone into the CNS.
Both myelinated and nonmyelinated ﬁbers were found to
have grown in the spinal cord where they projected into the
gray matter, formed functional connections and improved
sensorimotor recovery of the animals [99]. In another study,
artiﬁcially induced RARβ2 expression also supported regen-
eration of descending corticospinal tract ﬁbers after midcer-
vical spinal cord injury (Figure 4). Again, the induced regen-
eration of ﬁbers was accompanied by improved sensory and
locomotor behavior [100]. These data suggest not only that
RARβ is involved in activating a physiological program of re-
generation but also that retinoic acid signaling may be used
as a therapeutic tool in spinal cord injury.
5.2. ManipulationofRAR/RXRsignalinginthe
peripheralnervoussystem
As mentioned above, it has been known for some time that
retinoids act as neurotrophic factors for sympathetic and
sensory neurons of the peripheral nervous system [20–24].
However, very few studies have addressed the role of RA
in peripheral nerve regeneration in vivo. Taha and cowork-
ers tested whether local RA injections improved morpho-
logical and functional regeneration of tibial nerves under-
going anastomosis. They showed that animals injected lo-
cally with RA exhibited increased axonal density when com-
pared to vehicle-treated animals [101]. Several cell culture
experiments suggested that RA eﬀects may involve an up-
regulation of neurotrophin receptors, and molecular stud-
ies indicate mutually synergistic inﬂuences of the RA- and
neurotrophin-signaling pathways. Nerve growth factor in-
duced the RA-synthesizing enzyme RALDH in dorsal root
ganglia [23] and activated the RARβ promoter [30]. RA, on
the other hand, caused expression of various neurotrophin
r e c e p t o r s( s e e[ 5, 90] for review). That synergistic inter-
actions between RA and neurotrophins take place in vivo
was revealed in a study using a mouse model for diabetes
[102]. Treatment of the animals with all-trans RA via sub-
cutaneous injection in a dose of 20mg/kg was able to prevent
the NGF depletion normally seen in diabetic mice. Micro-
scopic analysis subsequently showed that diabetes-associated
loss of Schwann cells, of myelinated, and of nonmyelinated
axons was strongly reduced by RA. This beneﬁcial eﬀect was
also measurable in behavioral tests of sensory-motor func-
tions [102].
5.3. RetinoidsandPPARligandsinpainsignaling
In a diﬀerent line of research about spinal cord sensitiza-
tion, some contrasting results were obtained recently. To in-
vestigate whether retinoids might be involved in the pro-
cessing of nociceptive information, especially in situations
of hyperalgesia due to inﬂammation, rats were given 10–
15mg/kg all-trans RA orally for 4 days. Electrophysiologi-
cal recordings revealed that treated animals had decreased
thresholds to mechanical and electrical stimulation of the
pawsandincreasedcutaneousreceptiveﬁelds.Thisincreased
responsiveness caused by RA was similar to hyperalgesia in-
duced by intraplantar administration of carrageenan (which
leads to local inﬂammation) [103]. On the molecular level,
RA induced changes of gene expression in the spinal cord,
for instance, an increase of COX-2 and IL-1. Inhibition of
these pathways with IL-1 receptor antagonist and the COX-
inhibitor dexketoprofen reduced responses to mechanical or
thermal stimulation when those had been sensitized with RA
[104]. In these studies, it was concluded that all-trans RA
induced changes in the spinal cord that are similar to in-
ﬂ a m m a t i o n .A tt h i sp o i n t ,i ti sd i ﬃcult to reconcile this con-
clusion with the anti-inﬂammatory properties when RA was
combined with stimuli of bacterial infection or Aβ deposi-
tion.
In contrast to RA, administration of the PPARα ago-
nists GW7647, Wy14643, perﬂuorooctanoic acid, and PEA
reduced nocifensive behaviors in various animal models of
hyperalgesia, implicating a mitigating role of PPAR in the
regulation of pain signaling [43, 44]. GW7647 and PEA also
prevented ﬁring of spinal cord nociceptive neurons in rats
after peripheral exposure to formalin[44].S. van Neerven and J. Mey 9
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Figure 4: Transfection of RARβ induces regeneration of corticospinal axons in vivo. (a) Longitudinal sections of the adult rat spinal cord
were traced with BDA to determine ﬁbre regeneration in the corticospinal tract; overview of the lesion site in an animal injected with the
RARβ2 expressing construct (EIAV-RARβ2, Rostral: left). (b) Animals with RARβ2-transfected cells displayed less ﬁber degeneration than
control rats. (c) Labeled axons were detected up to the edge of the lesion, (d) at the distal edge of the lesion, and (e—g) at various distances
caudal to the lesion. Growth cone-like endings were detected at the tips of some axons (white arrowheads in d). Axons appear to send
collaterals (white arrowhead in g) from white matter to grey matter. (Scale bars in (a): 1mm, in (b—g): 100μm.) (h—i) Quantiﬁcation of
BDA-labeled ﬁbres in the corticospinal tract after spinal cord lesion. EIAV-RARβ2-treated animals displayed increased ﬁber numbers rostral
and caudal to the lesion compared to control animals (P<. 05, two-way ANOVA) (source: [100]).
5.4. UseofPPARligandsasanti-inﬂammatory
treatmentafterspinalcordinjury
The knowledge about anti-inﬂammatory properties of PPAR
ligands obtained in cell cultures soon prompted animal ex-
periments. In these, PPARα ligands were indeed shown to
exert neuroprotective eﬀects after traumatic brain injury
[105]. Recently, it was discovered that synthetic PPARγ lig-
ands rosiglitazone and pioglitazone are also neuroprotective
by reducing the inﬂammation in the spinal cord. Treatment10 PPAR Research
Table 1: Anti-inﬂammatory eﬀects of PPARα and PPARγ agonists on the molecular level.
Experimental system Nuclear receptor Regulated signals Reference
Cytokine- and LPS-stimulated microglia PPARα,RXR NO synthesis, IL-1β, IL-6, IL-12p40, TNFα,M C P - 1 [ 78]
Activated macrophages PPARα, γ iNOS, heme ogygenase (COX-2, HSP70 not aﬀected) [70]
Activated macrophages PPARγ iNOS, MMP-9, scavenger receptor A [80]
Activated human monocytes PPARγ IL-1β,I L - 6 ,T N F α [81]
Activated macrophages PPARγ Reactive oxigen species [77]
LPS-stimulated microglia PPARγ IL-1β,I L - 6 ,T N F α, MCP-1, iNOS [87]
LPS-stimulated microglia PPARγ IL-6, TNFα, iNOS, COX-2 [85]
Aβ-stimulated microglia PPARγ IL-6, TNFα, COX-2 [82]
LPS-stimulated astrocytes PPARα, RXR IL-1β,I L - 6 ,T N F α, iNOS, MCP-1 [88]
LPS-stimulated astrocytes PPARγ IL-6, TNFα, iNOS, COX-2 [85]
LPS-stimulated astrocytes PPARγ IL-1β,I L - 6 ,T N F α, MCP-1, iNOS [87]
Cerebellar injection of IFNγ, LPS PPARγ iNOS, cell death [89]
MPTP-treated mice PPARγ iNOS, IκB, cell death [86]
APPV717I transgenic mice PPARγ iNOS, COX-2, β-amyloid [83]
Rat spinal cord injury PPARγ IRF-1, IL-1β, IL-6, MCP-1, ICAM, Egr-1 [106]
Rat model for stroke PPARγ IL-1β, iNOS, COX-2 [107]
of rats directly after SCI resulted in a decreased lesion site,
better survival of motor neurons, sparing of myelin, reduced
astrogliosis, and less microglial activation. These features
were accompanied by enhanced functional motor recovery
and reduced hyperalgesia [106]. Investigation of gene ex-
pression revealed that pioglitazone lowered levels of tran-
scription factors IRF-1, NFκB, transmembrane proteins Egr-
1, ICAM, and cytokine/chemokines IL-1β, IL-6, MCP-1, but
increased expression of neuroprotective genes and antioxi-
dant enzymes. In a rat model for stroke (middle cerebral
artery occlusion), PPARγ ligands were able to improve neu-
rological outcome, decreased infarct size, and reduced in-
ﬂammation. Fewer microglia/macrophages appeared to be
present, and transcript and protein levels of IL-1, COX-2,
and iNOS were also lower [107].
6. CONCLUSION
The studies discussed here demonstrate that RAR/RXR and
PPAR/RXR signaling may be therapeutic targets after spinal
cordinjury.ThemainpotentialofPPARligandsderivesfrom
their anti-inﬂammatory capacity, which has been corrobo-
rated in rodent models of inﬂammation involving various
peripheral organs. After spinal cord injury, inﬂammatory re-
actions account for a large proportion of the secondary dam-
agetoneuronsandoligodendrocytes.Inthiscontext,ﬁrstex-
perimentsshowthatPPARligandsareneuroprotective.Since
PPAR activators are already in use to treat diabetes, clinical
studiesafterstokeorotherkindsofCNSdamagearetobeex-
pected. While retinoids also have anti-inﬂammatory proper-
ties, they exert more direct eﬀects on the nerve tissue. In sev-
eral populations of neurons, axonal regeneration can be in-
duced or supported by the activation of RAR/RXR signaling.
Since systemic application of retinoic acid inﬂuences neu-
ral physiology within the CNS, therapeutic possibilities arise
here as well. As in the case of cancer treatment, an important
consideration is the expression of retinoid receptors. After
spinal cord injury the induction of RARβ appears to be a re-
quirement. In addition to the classical transcriptional eﬀects,
retinoids and PPAR ligands can act via receptor-independent
mechanisms. This, however, is a largely uncharted territory
where therapeutic beneﬁts remain to be discovered.
ABBREVIATIONS
Aβ: Beta amyloid peptide
ADH: Alcohol dehydrogenase
AP: Activating protein
BDA: Biotinylated dextran amine
BDNF: Brain-derived neurotrophic factor
CNS: Central nervous system
CNTF: Ciliary neurotrophic factor
COX: Cyclooxygenase
CRABP: Cellular retinoic acid binding
protein
CRBP: Cellular retinol binding protein
dpo: dies post operationem
EGF: Epidermal growth factor
Egr: EGF receptor
ErbB: Tyrosine kinase related to the EGF
recaptor
GAP43: Growth associated protein 43
ICAM: Intercellular cell adhesion
molecule
IFN: Interferon, IL–interleukin
iNOS: Inducible NO synthase
IRF: Interferon regulatory factor
LPS: Lipopolysaccharide
LTB4 : Leukotriene B4
MCP: Macrophage chemoattractant
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MIP: Macrophage inﬂammatory protein
MMP: Matrix metalloproteinase
MPTP: 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine
NFκB: Nuclear factor κB
NGF Nerve growth factor
NR(plus number): Nuclear receptor
PEA: Palmitoyl ethanolamide
15d-PGJ2: 15-deoxy-delta prostaglandin J2
PI3-K: Phosphoinositide 3-kinase
PNS: Peripheral nervous system
PPAR: Peroxisome proliferator-activated
receptor
PPRE: PPAR response element
RA: Retinoic acid
RALDH: Retinaldehyde dehydrogenase
RAR: Retinoic acid receptor
RARE: Retinoic acid response element
RXR: Retinoid X receptor
SCI: Spinal cord injury
STAT: Signal transducer and activator of
transcription
TGF: Transforming growth factor
TNF: Tumor necrosis factor
TR: Thyroid hormone receptor
TTNPB: 4-[(E)-2-(5,6,7,8-tetrahydro-
5,5,8,8-tetramethyl-2-
naphthalenyl)-1-propenyl]
benzoic acid
2,4-TZD: 2,4-thiazolidinedione
VCAM: Vascular cell adhesion molecule
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